IL6 and COVID-19: For example, tocilizumab (a monoclonal antibody against IL6) and convalescent plasma therapy (CPT) reduced IL6 concentrations, controlled and relieved inflammation, and managed the cytokine storm in COVID-19 patients (112–115).